Summary of Key Points
Qilekang, a pioneer in China's pharmaceutical e-commerce industry, owns the chronic disease healthcare platform Guoliuyunyi. After its stock debuted on NASDAQ in October 2025, the price plummeted from $4 to $0.065 (a penny stock). The company managed to avoid delisting by consolidating 18 shares into one, bringing the price back up to $1, but this move has sparked a class-action lawsuit from investors. The collapse is attributed to various issues, including speculative trading, the release of restricted shares by original shareholders, continuous losses, and competition from market giants for traffic. What was once a star company valued at over $20 billion is now facing a dual crisis of capital and business problems.
I. The Stock Price Plunge: Two Different Reasons for the Two Drops
The stock price collapse of Guoliuyunyi occurred in two separate instances, each with different underlying causes:
First Drop (December 2025): Speculative Trading
Two months after the listing, the price dropped sharply from $5.42 to $0.5 ($90% decrease). The main reason was the company's extremely low number of outstanding shares—only 5 million shares were issued during the IPO (less than 5% of the total capital stock), making it easy for large funds to manipulate the price. The U.S. stock market allows "T+0" trading (buy and sell on the same day) and short-selling (borrowing stocks to sell and then buying them back at a lower price). Speculators sold shares at high prices and bought them back at low prices, driving the price down.
Second Drop (May 2026): Shareholders Fleeing the Market
In April, the restricted shares of original shareholders were released (15 million shares that could no longer be sold), and institutions such as Buchang Pharmaceutical and Gaotejia began to plan to sell their holdings. Since the price had already been significantly weakened by speculative trading, shareholders rushed to cash out, causing the price to drop to $0.075. Buchang Pharmaceutical (holding 15% of the shares) had previously forecast a loss of $300 million and is now suffering even greater losses.
II. From “Number One in Pharmaceutical E-commerce” to Transitioning to Internet Healthcare: Ambition Meets Reality
Qilekang once had a strong foundation:
- In 2010, it capitalized on the rise of Tmall's pharmaceutical section and remained the number one player in pharmaceutical e-commerce for five consecutive years, with a valuation of over $20 billion. It also received investments from firms like Sequoia and JD.com.
- In 2015, the company decided to transition to internet healthcare by launching the Qilekang Doctor app, targeting patients with chronic diseases who frequently purchase medication and have high loyalty. The idea was sound, but they overlooked the critical importance of traffic in the internet business model.
In 2016, Alibaba and JD.com started their own pharmaceutical businesses, pulling traffic away from third-party platforms like Qilekang. Without sufficient traffic, patients could no longer find the company's services, and the business came to a halt.
III. The “Game” of Capital: Going Public as a Way Out
Why did Guoliuyunyi insist on going public? Industry insiders suggest that some shareholders wanted to exit their investments:
- Qilekang suffered continuous losses, with net losses increasing from $36 million in 2023 to $130 million in 2025. Its revenue mainly came from low-margin drug sales, and it invested very little in research and development ($3 million in 2024), leaving no hope for turnaround.
- Investors were impatient: Institutions like Sequoia and Buchang had invested for many years and needed to cash out through a public offering. Even if the stock price plummeted, any return would be better than losing their investment completely.
At the listing ceremony, Shi Zhenyang expressed gratitude, possibly knowing that this was just a “dignified exit” strategy.
IV. The Lawsuit: A “Manipulation to Drive Out Investors”?
Some investors in the U.S. have filed lawsuits against Guoliuyunyi, accusing the company of deliberately manipulating the stock price to lure investors and then selling their shares at a profit. The amount involved is several million dollars.
Although the company managed to stabilize the price at $1 by consolidating shares (stocks below $1 on NASDAQ can lead to delisting), this merely masks the underlying issues: a unprofitable business, shareholders seeking to exit, and investors demanding accountability. Guoliuyunyi's path to survival is extremely difficult.
V. Lessons Learned: Why Did a Promising Company Fail So Hard?
Qilekang’s story serves as a caution for entrepreneurs and investors:
1. Traffic is King: In the age of internet commerce, it’s essential not to lose control of your own traffic. Transitioning to internet healthcare is a valid strategy, but relying on third-party platforms (like Tmall and JD.com) can be fatal if those platforms cut off traffic.
2. Capital is a Double-Edged Sword: While it can help you expand quickly, it can also force you to go public for quick profits, sometimes at the expense of your business’s long-term health.
3. Be Cautious with Small-Cap Stocks in the U.S. Market: Companies with few outstanding shares are vulnerable to speculative trading on NASDAQ. Ordinary investors should avoid following such trends.
What was once the “number one pharmaceutical e-commerce company” has become a cautionary tale in the capital market, highlighting the challenges of ambition, capital, and reality in business. Entrepreneurship is difficult, and maintaining success even more so.